News | May 01, 2025
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
Alembic Pharmaceuticals commissions new facility at Pithampur
Alembic Pharmaceuticals commissions new facility at Pithampur
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
Subscribe To Our Newsletter & Stay Updated
